Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition JA Dahl, I Jung, H Aanes, GD Greggains, A Manaf, M Lerdrup, G Li, ... Nature 537 (7621), 548-552, 2016 | 544 | 2016 |
Breast cancer quantitative proteome and proteogenomic landscape HJ Johansson, F Socciarelli, NM Vacanti, MH Haugen, Y Zhu, I Siavelis, ... Nature communications 10 (1), 1600, 2019 | 180 | 2019 |
Nuclear legumain activity in colorectal cancer MH Haugen, HT Johansen, SJ Pettersen, R Solberg, K Brix, K Flatmark, ... PloS one 8 (1), e52980, 2013 | 100 | 2013 |
Cystatin E/M suppresses legumain activity and invasion of human melanoma JJ Briggs, MH Haugen, HT Johansen, AI Riker, M Abrahamson, ... BMC cancer 10, 1-13, 2010 | 96 | 2010 |
High expression of the cysteine proteinase legumain in colorectal cancer–Implications for therapeutic targeting MH Haugen, K Boye, JM Nesland, SJ Pettersen, EV Egeland, T Tamhane, ... European journal of cancer 51 (1), 9-17, 2015 | 72 | 2015 |
Intra-and extracellular regulation of activity and processing of legumain by cystatin E/M R Smith, HT Johansen, H Nilsen, MH Haugen, SJ Pettersen, ... Biochimie 94 (12), 2590-2599, 2012 | 70 | 2012 |
Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells T Tamhane, S Lu, GM Maelandsmo, MH Haugen, K Brix Biochimie 122, 208-218, 2016 | 68 | 2016 |
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer MT Grinde, B Hilmarsdottir, HM Tunset, IM Henriksen, J Kim, MH Haugen, ... Breast Cancer Research 21, 1-13, 2019 | 58 | 2019 |
Proteolysis mediated by cysteine cathepsins and legumain—recent advances and cell biological challenges K Brix, J McInnes, A Al-Hashimi, M Rehders, T Tamhane, MH Haugen Protoplasma 252, 755-774, 2015 | 51 | 2015 |
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors K Seip, KG Fleten, A Barkovskaya, V Nygaard, MH Haugen, ... Oncotarget 7 (15), 19997, 2016 | 45 | 2016 |
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer EM Lindholm, M Ragle Aure, MH Haugen, K Kleivi Sahlberg, ... Molecular oncology 13 (10), 2278-2296, 2019 | 39 | 2019 |
Basal‐like breast cancer engages tumor‐supportive macrophages via secreted factors induced by extracellular S100A4 L Prasmickaite, EM Tenstad, S Pettersen, S Jabeen, EV Egeland, S Nord, ... Molecular oncology 12 (9), 1540-1558, 2018 | 37 | 2018 |
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro LS Normann, MR Aure, SK Leivonen, MH Haugen, V Hongisto, ... Scientific reports 11 (1), 10893, 2021 | 30 | 2021 |
Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions NN Lunde, MH Haugen, KBB Larsen, I Damgaard, SJ Pettersen, R Kasem, ... Biochimie 139, 27-37, 2017 | 29 | 2017 |
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer K Boye, JM Nesland, B Sandstad, M Haugland Haugen, GM Mælandsmo, ... British journal of cancer 107 (4), 667-674, 2012 | 27 | 2012 |
Targeting AXL and the DNA damage response pathway as a novel therapeutic strategy in melanoma K Flem-Karlsen, E McFadden, N Omar, MH Haugen, GF Øy, T Ryder, ... Molecular cancer therapeutics 19 (3), 895-905, 2020 | 26 | 2020 |
The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse G Hetland, DM Eide, JM Tangen, MH Haugen, MR Mirlashari, JE Paulsen PLoS One 11 (12), e0167754, 2016 | 24 | 2016 |
AXL inhibition improves BRAF-targeted treatment in melanoma M Nyakas, KG Fleten, MH Haugen, N Engedal, C Sveen, IN Farstad, ... Scientific Reports 12 (1), 5076, 2022 | 22 | 2022 |
Consortia Oslo Breast Cancer Research Consortium (OSBREAC) HJ Johansson, F Socciarelli, NM Vacanti, MH Haugen, Y Zhu, I Siavelis, ... Socciarelli, F, 1-14, 2019 | 16 | 2019 |
miR-101-5p acts as a tumor suppressor in HER2-positive breast cancer cells and improves targeted therapy LS Normann, MH Haugen, MR Aure, VN Kristensen, GM Mælandsmo, ... Breast Cancer: Targets and Therapy, 25-39, 2023 | 13 | 2023 |